$GYRE News

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est

Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate

Gyre Therapeutics Appoints Three New Members to its Board of Directors

New Strong Sell Stocks for May 27th

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics New Drug Application For Chronic Hepatitis B Treatment Receives China's Center For Drug Evaluation Acceptance

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est

Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics Gets Priority Review In China For Hepatitis B Liver Damage Drug

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Gyre Therapeutics Sees FY2026 Sales $100.500M-$111.000M vs $146.133M Est

Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates

Gyre Therapeutics shares are trading higher after the company announced it agreed to acquire Cullgen for approximately $300 million.